Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Immune Efficacy Study for Primary Prevention Using Intranasal Insulin Therapy in Islet Autoantibody Negative Children at High Genetic Risk for Type 1 Diabetes

NCT03182322 is registered in ClinicalTrials.gov with Technical University of Munich as lead sponsor.

NCT NCT03182322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03182322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Immune Efficacy Study for Primary Prevention Using Intranasal Insulin Therapy in Islet Autoantibody Negative Children at High Genetic Risk for Type 1 Diabetes
Lead sponsor
Technical University of Munich
Phase
Phase 2
Overall status
Completed
Start date
May 25, 2018
Completion date
June 7, 2021
Enrollment
38 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1